
Opinion|Videos|September 9, 2024
JAK Inhibitors in Atopic Dermatitis
A panel of dermatologists discuss the evolution of JAK inhibitors for atopic dermatitis and how they fit into current treatment paradigms.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- A number of JAK inhibitors, both oral (abrocitinib, upadacitnib) and topical (ruxolitinib cream), are FDA approved for atopic dermatitis.
- How have JAK inhibitors evolved over the years?
- How have differences between JAK inhibitors led to differences in their safety and efficacy profiles?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Inhaled Treprostinil Improves IPF Outcomes in Phase 3 TETON-1 Trial
2
Diabetes Technology at a Turning Point: What’s New and What’s Next, With Rachael Sood, NP
3
What We Still Don't Know: Gaps, Phototherapy, and the Future of Pediatric Eczema Care
4
When and How to Escalate Pediatric Atopic Dermatitis Treatment
5























































